Xenon Pharmaceuticals (NASDAQ:XENE) Insider Andrea Difabio Sells 1,342 Shares

Key Points

• Insider sale: Andrea Difabio sold 1,342 Xenon shares on March 13 at an average price of $55.23 for $74,118.66, leaving her with 7,301 shares (a 15.53% ownership decrease); she also sold 2,607 shares on March 10 at $60.11.
• Company context — mixed signals: Xenon completed the X‑TOLE2 Phase‑3 study for XEN1101 and closed an upsized public offering raising about $747.5M alongside several analyst upgrades (consensus "Buy," $71.94 target), but the financing and reported insider sales (including the CEO) raise dilution and optics concerns that could pressure near‑term per‑share metrics.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) insider Andrea Difabio sold 1,342 shares of Xenon Pharmaceuticals stock in a transaction on Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the transaction, the insider directly owned 7,301 shares of the company's stock, valued at $403,234.23. This represents a 15.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Andrea Difabio also recently made the following trade(s):

• On Tuesday, March 10th, Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock. The shares were sold at an average price of $60.11, for a total value of $156,706.77.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE traded down $2.67 during mid-day trading on Friday, reaching $55.23. The company had a trading volume of 3,849,961 shares, compared to its average volume of 1,923,723. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $63.95. The firm has a market cap of $4.59 billion, a price-to-earnings ratio of -12.67 and a beta of 0.91. The business's 50-day simple moving average is $43.71 and its 200 day simple moving average is $41.92.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the company earned ($0.84) EPS. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on XENE. Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday. Wells Fargo & Company upped their target price on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an "overweight" rating in a research note on Tuesday. Chardan Capital raised Xenon Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, November 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Finally, Needham & Company LLC upped their price objective on Xenon Pharmaceuticals from $58.00 to $80.00 and gave the stock a "buy" rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $71.94.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Cinctive Capital Management LP grew its stake in shares of Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company's stock worth $1,045,000 after buying an additional 263 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of Xenon Pharmaceuticals by 1.8% in the 3rd quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company's stock valued at $774,000 after acquiring an additional 334 shares during the last quarter. State of Wyoming lifted its stake in shares of Xenon Pharmaceuticals by 30.4% in the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 350 shares during the last quarter. Quarry LP boosted its holdings in shares of Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 500 shares in the last quarter. Finally, Altfest L J & Co. Inc. grew its position in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company's stock worth $369,000 after acquiring an additional 501 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company's stock.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase‑3 progress — Xenon completed the X‑TOLE2 Phase 3 study, placing XEN1101 (azetukalner) in focus for epilepsy investors and supporting a planned NDA timeline; this derisks the lead program and underpins longer‑term commercial value. Read More.
• Positive Sentiment: Big institutional interest — Reports note major funds increasing exposure (including a ~$200M position cited by The Motley Fool), which can add buying pressure into the stock on further positive catalysts. Read More.
• Positive Sentiment: Balance‑sheet boost — Xenon closed an upsized public offering that raised approximately $747.5M of gross proceeds, extending runway for Phase 3/commercial preparations and reducing near‑term financing risk. Read More.
• Positive Sentiment: Analyst upgrades — Several brokers raised price targets and reiterated Buy/Overweight ratings (Deutsche Bank, HC Wainwright, Wells Fargo and others), which can support short‑term demand. Read More.
• Neutral Sentiment: Model adjustments — HC Wainwright revised multi‑year EPS forecasts (improving FY2028–FY2030 assumptions but nudging FY2027), reflecting evolving commercialization timing; useful for context but subject to change. Read More.
• Neutral Sentiment: Volume and momentum — The stock has seen elevated trading volume following the analyst activity and trial news, which can amplify intraday moves in either direction. Read More.
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (hundreds of thousands of shares by the CEO), reducing insider ownership and raising optics concerns for some investors. Read More.
• Negative Sentiment: Dilution risk — The sizable share issuance (and initial underwriter option) that funded the ~$747.5M raise increases outstanding shares and can pressure near‑term per‑share metrics despite improving cash runway. Read More.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.